Insights

The AVITA Medical (ASX: AVH) share price plummets almost 6% in early trade

The AVITA share price is in focus this morning following release of the company’s 2Q21 results. Here’s a summary.
The post The AVITA Medical (ASX: AVH) share price plummets almost 6% in early trade appeared first on The Motley Fool Australia. –

Two men react in shock at IGO share price drop

The AVITA Medical Inc (ASX: AVH) share price has plunged in opening trade today after the company released its second-quarter results for the fiscal year 2021

At the time of writing, the AVITA share price is trading at 5.85% lower at $6.55.

AVITA Medical is a regenerative medicine group that aims to address unmet medical needs in burn injuries, trauma injuries, chronic wounds and dermatological and aesthetics indications. The company endeavours to advance care for burn patients with its novel technology platform, the RECELL System. AVITA is also listed on the NASDAQ stock exchange in the United States under the ticker RCEL.

Let’s take a look at its quarterly results for the period ended 31 December 2020.

Financial results

The company reported a US-based RECELL revenue of $5.0 million. This is a 62% increase compared to the same quarter of the prior year.

Total global revenue increased 57% compared to the previous corresponding period (pcp), coming in at $5.1 million.

Operating expenses decreased to $10.4 million for the period compared to $13.4 million in the pcp.  AVITA attributes the savings partially to lower legal costs and lower stock-based compensation.

As of 31 December 2020, the company held $59.8 million in cash.

AVITA did not provide financial guidance due to current uncertainty stemming from coronavirus. The company advised that because it gained its revenue via 20 accounts with physicians, its accounts were susceptible to the impacts of COVID-19. This was currently creating an unpredictable business space.

AVITA reported a net loss of $5.6 million for the quarter, compared to the net loss of $10.5 million for the same quarter in the previous year.

CEO commentary and AVITA share price snapshot

AVITA Medical CEO Dr Mike Perry made the following comments:

I’m proud of our progress over the last quarter as we strive to broaden the applications of our platform to serve patients. With our burn centre account base now mostly built out, our sales team is poised and ready to drive utilisation as the pandemic abates and we regain access to hospitals and patients.

We have continued to make strong progress with our vitiligo pivotal trial, seeing very encouraging interest and enrolment trends, and we believe this could put us in a position to file for FDA approval in 2022.

The AVITA Medical share price has fallen more than 56% over the previous 12-month period. Year-to-date, the share price has gained around 44%.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The AVITA Medical (ASX: AVH) share price plummets almost 6% in early trade appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!